ANEXSIA 5/325 Drug Patent Profile
When do Anexsia 5/325 patents expire, and what generic alternatives are available?
Anexsia 5/325 is a drug marketed by Specgx Llc and is included in one NDA.
The generic ingredient in ANEXSIA 5/325 is acetaminophen; hydrocodone bitartrate. There is one drug master file entry for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the acetaminophen; hydrocodone bitartrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANEXSIA 5/325?
- What are the global sales for ANEXSIA 5/325?
- What is Average Wholesale Price for ANEXSIA 5/325?
Summary for ANEXSIA 5/325
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 661 |
| DailyMed Link: | ANEXSIA 5/325 at DailyMed |
Pharmacology for ANEXSIA 5/325
| Drug Class | Opioid Agonist |
| Mechanism of Action | Opioid Agonists |
US Patents and Regulatory Information for ANEXSIA 5/325
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | ANEXSIA 5/325 | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 040409-001 | Oct 20, 2000 | AA | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
